Future directions for the use of hypomethylating agents

Seminars in Hematology

Volumn 42, Issue SUPPL. 2, 2005, Pages

  Garcia Manero, Guillermo ^a   Gore, Steven D ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 5 AZA 2' DEOXYCYTIDINE; AMSACRINE; ANTHRACYCLINE; ANTIINFECTIVE AGENT; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; BUSULFAN; BUTYRIC ACID DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSINE DERIVATIVE; CYTOTOXIC AGENT; DAUNORUBICIN; DEPSIPEPTIDE; ERYTHROPOIETIN; FR 901228; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; IDARUBICIN; IMATINIB; IMMUNOMODULATING AGENT; LBH 589; METHYLTRANSFERASE INHIBITOR; MG 98; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHROMATIN; CLINICAL TRIAL; DEACETYLATION; DNA SEQUENCE; EPIGENETICS; HEMATOLOGIC DISEASE; HUMAN; METHYLATION; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SICKLE CELL ANEMIA; SOLID TUMOR; STOMACH DISEASE; THROMBOCYTOPENIA;

EID: 21844480363     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2005.05.004     Document Type: Article

References (85)

1. R. Abele, M. Clavel, P. Dodion The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas Eur J Cancer Clin Oncol 23 1987 1921 1924
2. F. Antequera, A. Bird Number of CpG islands and genes in human and mouse Proc Natl Acad Sci U S A 90 1993 11995 11999
3. H. Anzai, P. Frost, J.L. Abbruzzese Synergistic cytotoxicity with 2′-deoxy-5-azacytidine and topotecan in vitro and in vivo Cancer Res 52 1992 2180 2185
4. K.E. Bachman, B.H. Park, I. Rhee Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene Cancer Cell 3 2003 89 95
5. A.J. Bannister, R. Schneider, T. Kouzarides Histone methylation Dynamic or static? Cell 109 2002 801 806
6. T.H. Bestor, G.L. Verdine DNA methyltransferases Curr Opin Cell Biol 6 1994 380 389
7. E.E. Cameron, K.E. Bachman, S. Myohanen Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nat Genet 21 1999 103 107
8. B.I. Carr, J.G. Reilly, S.S. Smith The tumorigenicity of 5-azacytidine in the male Fischer rat Carcinogenesis 5 1984 1583 1590
9. S. Charache, G. Dover, K. Smith Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex Proc Natl Acad Sci U S A 80 1983 4842 4846
10. S. Charache, M.L. Terrin, R.D. Moore Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia N Engl J Med 332 1995 1317 1322
11. M. Clavel, S. Monfardini, S. Fossa 5-Aza-2′-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 1992 399 400
12. M. Daskalakis, T.T. Nguyen, C. Nguyen Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′- deoxycytidine (decitabine) treatment Blood 100 2002 2957 2964
13. A.J. Davis, K.A. Gelmon, L.L. Siu Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks Invest New Drugs 21 2003 85 97
14. M. de Lima, F. Ravandi, M. Shahjahan Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias Cancer 97 2003 1242 1247
15. J. DeSimone, P. Heller, L. Hall 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons Proc Natl Acad Sci U S A 79 1982 4428 4431
16. J. DeSimone, P. Heller, R.E. Molokie Tetrahydrouridine, cytidine analogues, and hemoglobin F Am J Hematol 18 1985 283 288
17. J. DeSimone, M. Koshy, L. Dorn Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia Blood 99 2002 3905 3908
18. M. Duvic, R. Talpur, N. Chiao Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) Blood 102 2003 179a (abstr)
19. J.A. Fahrner, S. Eguchi, J.G. Herman Dependence of histone modifications and gene expression on DNA hypermethylation in cancer Cancer Res 62 2002 7213 7218
20. X. Fang, C. Zheng, Z. Liu Enhanced sensitivity of prostate cancer DU145 cells to cisplatinum by 5-aza-2′-deoxycytidine Oncol Rep 12 2004 523 526
21. P. Frost, J.L. Abbruzzese, B. Hunt Synergistic cytotoxicity using 2′-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells Cancer Res 50 1990 4572 4577
22. F. Fuks, W.A. Burgers, A. Brehm DNA methyltransferase Dnmt1 associates with histone deacetylase activity Nat Genet 24 2000 88 91
23. G. Garcia-Manero, J. Daniel, T.L. Smith DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia Clin Cancer Res 8 2002 2217 2224
24. Garcia-Manero G, Issa JP: Histone deacetylase inhibitors: A review of their clinical status as antineoplastic agents. Cancer Invest (in press)
25. G. Garcia-Manero, J.P. Issa, J. Cortes Phase I study of oral suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in patients with advanced leukemias or myelodysplastic syndromes (MDS) Proc Am Soc Clin Oncol 23 2004 201 (abstr)
26. G. Garcia-Manero, S. Jeha, J. Daniel Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia Cancer 97 2003 695 702
27. G. Garcia-Manero, H.M. Kantarjian The hyper-CVAD regimen in adult acute lymphocytic leukemia Hematol Oncol Clin North Am 14 2000 1381 1396
28. G. Garcia-Manero, H.M. Kantarjian, B. Sanchez-Gonzales Results of a phase I/II study of the combination of 5-aza-2′-deoxycytidine (DAC) and valproic acid (VPA) in patients with leukemia Blood 104 2004 263
29. S. Gore, S.B. Baylin, T. Dauses Changes in promoter methylation and gene expression in patients with MDS and MDs-AML treated with 5-azacytidine and sodium phenylbutyrate Blood 104 2004 469 (abstr)
30. S.D. Gore, M.A. Carducci Modifying histones to tame cancer clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors Expert Opin Investig Drugs 9 2000 2923 2934
31. S.D. Gore, D. Samid, L.J. Weng Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells Clin Cancer Res 3 1997 1755 1762
32. S.D. Gore, L.J. Weng, S. Zhai Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia Clin Cancer Res 7 2001 2330 2339
33. M. Gottlicher, S. Minucci, P. Zhu Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells EMBO J 20 2001 6969 6978
34. P.A. Grant A tale of histone modifications Genome Biol 2 2001 REVIEW0003
35. J.G. Herman, S.B. Baylin Gene silencing in cancer in association with promoter hypermethylation N Engl J Med 349 2003 2042 2054
36. J.P. Issa, N. Ahuja, M. Toyota Accelerated age-related CpG island methylation in ulcerative colitis Cancer Res 61 2001 3573 3577
37. J.P. Issa, G. Garcia-Manero, F.J. Giles Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies Blood 103 2004 1635 1640
38. J.P. Issa, V. Gharibyan, J. Jelinek Hypomethylation dynamics following decitabine therapy in chronic myelogenous leukemia Blood 103 2004 A2956 (abstr)
39. P.A. Jones, S.B. Baylin The fundamental role of epigenetic events in cancer Nat Rev Genet 3 2002 415 428
40. H.M. Kantarjian, S. O'Brien, J. Cortes Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia Cancer 98 2003 522 528
41. A.R. Karpf, P.W. Peterson, J.T. Rawlins Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells Proc Natl Acad Sci U S A 96 1999 14007 14012
42. J.C. Keen, L. Yan, K.M. Mack A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine Breast Cancer Res Treat 81 2003 177 186
43. Y. Kondo, L. Shen, J.P. Issa Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer Mol Cell Biol 23 2003 206 215
44. M. Koshy, L. Dorn, L. Bressler 2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia Blood 96 2000 2379 2384
45. A. Lal, E. Vichinsky The role of fetal hemoglobin-enhancing agents in thalassemia Semin Hematol 41 2004 17 22
46. R. Lenzi, J.L. Abbruzzese, B. Hunt Reversal of cisplatinum resistance by 5-aza-2′-aza-deoxycytidine (DAC) in human ovarian cell lines Proc Am Assoc Cancer Res 33 1992 497 (abstr)
47. C.H. Lowrey, A.W. Nienhuis Brief report Treatment with azacitidine of patients with end-stage beta-thalassemia N Engl J Med 329 1993 845 848
48. F. Lyko, D. Stach, A. Brenner Quantitative analysis of DNA methylation in chronic lymphocytic leukemia patients Electrophoresis 25 2004 1530 1535
49. P. Marks, R.A. Rifkind, V.M. Richon Histone deacetylases and cancer causes and therapies Nat Rev Cancer 1 2001 194 202
50. F. Mavilio, A. Giampaolo, A. Care Molecular mechanisms of human hemoglobin switching selective undermethylation and expression of globin genes in embryonic, fetal, and adult erythroblasts Proc Natl Acad Sci U S A 80 1983 6907 6911
51. R.L. Momparler, D.Y. Bouffard, L.F. Momparler Pilot phase I-II study on 5-aza-2′-deoxycytidine (decitabine) in patients with metastatic lung cancer Anticancer Drugs 8 1997 358 368
52. C.T. Nguyen, D.J. Weisenberger, M. Velicescu Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine Cancer Res 62 2002 6456 6461
53. S.G. O'Brien, F. Guilhot, R.A. Larson Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004
54. A.H. Peters, J.E. Mermoud, D. O'Carroll Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin Nat Genet 30 2002 77 80
55. C.J. Phiel, F. Zhang, E.Y. Huang Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen J Biol Chem 276 2001 36734 36741
56. R.L. Piekarz, R.W. Robey, Z. Zhan T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance Blood 103 2004 4636 4643
57. R. Pili, M.P. Kruszewski, B.W. Hager Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis Cancer Res 61 2001 1477 1485
58. P. Pohlmann, L.P. DiLeone, A.I. Cancella Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix Am J Clin Oncol 25 2002 496 501
59. J.M. Quagliana, R.M. O'Bryan, L. Baker Phase II study of 5-azacytidine in solid tumors Cancer Treat Rep 61 1977 51 54
60. F. Ravandi, H. Kantarjian, A. Cohen Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant Results of a phase I study Bone Marrow Transplant 27 2001 1221 1225
61. K.D. Robertson, A.P. Wolffe DNA methylation in health and disease Nat Rev Genet 1 2000 11 19
62. H. Saba, C. Rosenfled, J.P. Issa First report of the phase III North American trial of decitabine in advanced myelodysplastic syndrome (MDS) Blood 104 2004 64 (abstr)
63. Y. Saunthararajah, J. DeSimone Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease Semin Hematol 41 2004 11 16
64. Y. Saunthararajah, C.A. Hillery, D. Lavelle Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease Blood 102 2003 3865 3870
65. Y. Saunthararajah, D. Lavelle, J. DeSimone DNA hypo-methylating agents and sickle cell disease Br J Haematol 126 2004 629 636
66. G. Schwartsmann, M.S. Fernandes, M.D. Schaan Decitabine (5-aza-2′-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia Preliminary observations Leukemia 11 suppl 1 1997 S28 S31
67. G. Schwartsmann, H. Schunemann, C.N. Gorini A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer Invest New Drugs 18 2000 83 91
68. C. Sessa, W. ten Bokkel Huinink, G. Stoter Phase II study of 5-aza-2′-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials Group Eur J Cancer 26 1990 137 138
69. L. Shen, M. Toyota, Y. Kondo Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia Blood 101 2003 4131 4136
70. L. Sigalotti, E. Fratta, S. Coral Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidine Cancer Res 64 2004 9167 9171
71. L.R. Silverman, E.P. Demakos, B.L. Peterson Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome A study of the Cancer and Leukemia Group B J Clin Oncol 20 2002 2429 2440
72. R. Singal, G.D. Ginder DNA methylation Blood 93 1999 4059 4070
73. B.D. Strahl, C.D. Allis The language of covalent histone modifications Nature 403 2000 41 45
74. D.A. Tagle, B.F. Koop, M. Goodman Embryonic epsilon and gamma globin genes of a prosimian primate (Galago crassicaudatus). Nucleotide and amino acid sequences, developmental regulation and phylogenetic footprints J Mol Biol 203 1988 439 455
75. T. Takahashi, N. Shivapurkar, J. Reddy DNA methylation profiles of lymphoid and hematopoietic malignancies Clin Cancer Res 10 2004 2928 2935
76. A. Thibault, W.D. Figg, R.C. Bergan A phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer Tumori 84 1998 87 89
77. M. Toyota, J.P. Issa CpG island methylator phenotypes in aging and cancer Semin Cancer Biol 9 1999 349 357
78. M. Toyota, K.J. Kopecky, M.O. Toyota Methylation profiling in acute myeloid leukemia Blood 97 2001 2823 2829
79. L.H. van der Ploeg, R.A. Flavell DNA methylation in the human gamma delta beta-globin locus in erythroid and nonerythroid tissues Cell 19 1980 947 958
80. J.B. Vermorken, S. Tumolo, K.J. Roozendaal 5-Aza-2′-deoxycytidine in advanced or recurrent cancer of the uterine cervix Eur J Cancer 27 1991 216 217
81. A.J. Weiss, G.E. Metter, T.F. Nealon Phase II study of 5-azacytidine in solid tumors Cancer Treat Rep 61 1977 55 58
82. P. Wijermans, M. Lubbert, G. Verhoef Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome A multicenter phase II study in elderly patients J Clin Oncol 18 2000 956 962
83. R. Willemze, S. Suciu, E. Archimbaud A randomized phase II study on the effects of 5-aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia An EORTC Leukemia Cooperative Group phase II study (06893) Leukemia 11 suppl 1 1997 S24 S27
84. H. Yang, K. Hoshino, B. Sanchez-Gonzalez Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid Leuk Res 29 2005 739 748
85. C.B. Yoo, J.C. Cheng, P.A. Jones Zebularine A new drug for epigenetic therapy Biochem Soc Trans 32 2004 910 912